Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Safety considerations with mycophenolate sodium.

Guido Filler1, Ilan Buffo

  • 1The University of Western Ontario, Department of Paediatrics, Children's Hospital of Western Ontario, Schulich School of Medicine & Dentistry, London, Ontario, Canada. guido.filler@lhsc.on.ca

Expert Opinion on Drug Safety
|August 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Why Do Adolescents and Young Adults Continue to Have the Worst Kidney Transplant Outcomes?

Pediatric transplantation·2026
Same author

Factors Affecting Medical Appointment Adherence among Adolescents and Young Adults with Kidney Disease: A Longitudinal Cohort Study.

Journal of pediatrics. Clinical practice·2026
Same author

Rethinking Creatinine in Children With Down Syndrome.

Acta paediatrica (Oslo, Norway : 1992)·2026
Same author

Mycophenolate dosing in childhood nephrotic syndrome.

The Lancet. Child & adolescent health·2026
Same author

Flatter Tacrolimus Pharmacokinetic Profiles in Pediatric Kidney Transplant Recipients Receiving Liquid Formulations: A Quality Improvement Study.

Pediatric transplantation·2026
Same author

Corrigendum to "Renal Autologous Cell Therapy to Stabilize Function in Diabetes-Related Chronic Kidney Disease: Corroboration of Mechanistic Action With Cell Marker Analysis" [<i>Kidney International Reports</i> Volume 7, Issue 7, July 2022, Pages 1619-1629].

Kidney international reports·2026

Enteric-coated mycophenolate sodium (EC-MPS) offers no significant gastrointestinal (GI) benefit over mycophenolate mofetil (MMF) in transplant patients. Both immunosuppressants demonstrate similar efficacy and safety profiles.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Mycophenolate mofetil (MMF) has been widely used for over a decade.
  • Enteric-coated mycophenolate sodium (EC-MPS) was developed as an alternative to MMF.
  • EC-MPS aims to reduce upper gastrointestinal (GI) side effects by releasing mycophenolic acid (MPA) in the small intestine, unlike MMF which absorbs in the stomach.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, and clinical trial data comparing EC-MPS and MMF.
  • To evaluate the efficacy, safety, and GI tolerability of EC-MPS versus MMF in solid-organ transplantation.

Main Methods:

  • Review of three randomized, controlled clinical trials comparing MMF and EC-MPS.
  • Analysis of pharmacological and pharmacokinetic data for both agents.

Related Experiment Videos

Main Results:

  • EC-MPS demonstrated similar efficacy and safety compared to MMF.
  • No significant improvement in GI side effects was observed with EC-MPS.
  • Bioequivalence dosing for EC-MPS was only established when co-administered with cyclosporine.

Conclusions:

  • EC-MPS is a safe and effective immunosuppressant for preventing acute rejection in renal transplantation.
  • The anticipated reduction in GI side effects with EC-MPS was not realized.
  • Further pharmacokinetic studies are needed for EC-MPS.